Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter ... (ng statements within the meaning of the ...)

HOME >> BIOLOGY >> TECHNOLOGY

Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments

Date:7/8/2009

ng statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Any statements that are not statements of historical fact (including, without limitation, statements containing the words "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements.

There are a number of important factors that could cause our actual results or events to differ materially from those indicated by such forward-looking statements, including risks relating to our ability to develop and maintain the necessary sales, marketing, supply chain, distribution and manufacturing capabilities to commercialize our products, including difficulties relating to the manufacture of Zyflo CR(R) tablets; the possibility that the Food and Drug Administration (the FDA) will take enforcement action against us or one or more of our marketed drugs that do not have FDA-approved marketing applications; patient, physician and third-party payor acceptance of our products as safe and effective therapeutic products; our ability to maintain regulatory approvals to market and sell our products that do have FDA approved marketing applications; our ability to enter into additional strategic licensing, collaboration or co-promotion transactions on favorable terms, if at all; our ability to maintain compliance with NASDAQ listing requirements; adverse side effects experienced by patients taking our products; difficulties relating to clinical trials, including difficulties or delays in the completion of patient enrollment, data collection or data analysis; the results of preclinical studies and clinical trials with respect to our products under development and whether such results will be indicative of results obtained in later clinical trials; our ability to satisfy FDA and other regulatory requirements; our ability to obt
'/>"/>

SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
2. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
3. Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
4. Cornerstone Therapeutics to Present at BioCenturys 2009 Future Leaders in the Biotech Industry Conference
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
7. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
8. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
9. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
10. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
11. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials

Post Your Comments:

(Date:12/14/2009)... Joins with State Biotech Leaders to Develop ... and Development while Boosting Rhode Island,s Growing ... PROVIDENCE, R.I., Dec. 14 Several ... research, medicine and biotechnology gathered today at ... the importance of medical innovation in Rhode ...

(Date:12/14/2009)... Dec. 14 Decision Resources, one of ... pharmaceutical and healthcare issues, finds that, owing to ... fibrillation drug market will increase more than sevenfold ... in 2018 in the United States, France, Germany, ... The new Pharmacor report entitled Atrial Fibrillation ...

(Date:12/11/2009)... Colo., December 10, 2009 miRagen Therapeutics, Inc., ... by developing innovative microRNA-based therapeutics for cardiovascular and ... demonstrating that microRNA-206 (miR-206) plays a crucial role ... or Lou Gehrig,s disease) and in neuromuscular synaptic ... the December 11 issue of the journal ...

(Date:12/11/2009)... -- Marrone Bio Innovations (MBI) today announces 2 ... Chris Hildreth joined MBI as Senior Vice President ... all commercial aspects of the company, including sales, ... (Ray) Lam joined MBI as Vice President of ... in scaling its broad pipeline of products to ...

Breaking Biology Technology:Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 2 Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 3 Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 4 The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2 miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2 Marrone Bio Innovations Announces Two New Executive Appointments 2 Marrone Bio Innovations Announces Two New Executive Appointments 3

[0] Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation'[0] The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 [0] miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease [0] Marrone Bio Innovations Announces Two New Executive Appointments

... , , , , 1 , ... 2 , Precautions and warnings , , ... , , 3.1, ... 3.2, Materials required but not supplied , , ...

... , , , , , ... , Eppendorf 5 Prime, Boulder, Colorado, , , ... The purity of DNA extracted from agarose gels can have a significant , ... using the are free of salts, ethidium , ...

... , , , , Jrgen Frhlich, Helmut ... for Microbiology , and Wine Research, , ... , , , , , , ... , The isolation of microorganisms (such as bacteria or yeast) from complex , ...

TripleMaster PCR System Eppendorf Perfectprep Gel Cleanup Kit Isolation of Microorganisms

(Date:12/11/2009)... GETTYSBURG, PAAs consumer demand for premium fruit increases, ... fruit to market. And to boost their bottom ... that can increase fruit quality while reducing labor ... by growers to produce larger, healthier fruit, is ... a significant impact on fruit production overhead, and, ...

(Date:12/11/2009)... cell manage to identify and degrade the diverse types ... serious diseases? The researchers Sabine C. Horn, Professor Thomas ... the Max Delbrck Center for Molecular Medicine (MDC) Berlin-Buch, ... puzzle. In an enzyme complex that plays a critical ... a scaffold regulating the identification and disposal of various ...

(Date:12/11/2009)... the deep ocean,s temperature variability and circulation system could ... deep ocean is affected more by surface warming than ... predictions of factors such as sea level rise and ... also been found to result in a more vigorous ... faster transport of large quantities of warm water, with ...

[0] Horizontal string trimmer reduces labor costs, increases peach size [0] MDC researchers identify a scaffold regulating protein disposal [0] New discoveries could improve climate projections

... drug abusers from relapsing, researchers at the University of ... Everitt, was able to reduce drug-seeking behaviours in rats ... and memory during the recall of drug-associated memories. ... Council, was reported in the 13 August issue of ...

... species around the world are a sign of a ... ilk, according to researchers from the University of California, ... in the journal Proceedings of the National Academy ... of amphibians and other plant and animal species add ...

... University of California, Davis, law professor Keith Aoki ... plants over the past several decades and speculates ... resources remain freely available across national borders to ... Controversies and Cases on Plant Genetic Resources and ...

Other Biology News:'Erasing' drug-associated memories may stop drug addiction relapses 2 Dying frogs sign of a biodiversity crisis 2 Dying frogs sign of a biodiversity crisis 3

'Erasing' drug-associated memories may stop drug addiction relapses Dying frogs sign of a biodiversity crisis 'Seed Wars: Controversies and Cases on Plant Genetic Resources and Intellectual Property'

Rabbit polyclonal to Staphylococcus Enterotoxin A (HRP) ( Abpromise for all tested applications)....

... with a modular approach to instrument control, ... Plus NDS family provides modular software components ... management, giving you the flexibility to choose ... now and that can grow as your ...

... Best: DASGIPs Process Control integrates Process ... comprehensive documentation for cultivation processes. A ... pH, dissolved oxygen, temperature and agitation ... Profiles, e.g. constant or scheduled media ...

... Microarrays designed for immunological studies, vaccine ... the flexible and powerful Paraflo microfluidic ... available as part of our comprehensive ... Custom Probe Content Probe content ...

Biology Products:

Rabbit Anti-Staphylococcus Enterotoxin A Polyclonal Antibody, Horseradish Peroxidase Conjugated from Abcam Agilent ChemStation Plus Networked Data Systems from Agilent Technologies DASGIP Process Control from DASGIP AG Custom Epitope Peptide Microarray from LC Sciences

Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter ...(ng statements within the meaning of the ...)